Department of Orthopaedic Surgery, New York University Medical Center, 301 East 17th Street, New York, NY, 10003, USA.
Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, 610041, China.
J Mol Med (Berl). 2018 Dec;96(12):1359-1373. doi: 10.1007/s00109-018-1703-0. Epub 2018 Oct 20.
Tay-Sachs disease (TSD) is a lethal lysosomal storage disease (LSD) caused by mutations in the HexA gene, which can lead to deficiency of β-hexosaminidase A (HexA) activity and consequent accumulation of its substrate, GM2 ganglioside. Recent reports that progranulin (PGRN) functions as a chaperone of lysosomal enzymes and its deficiency is associated with LSDs, including Gaucher disease and neuronal ceroid lipofuscinosis, prompted us to screen the effects of recombinant PGRN on lysosomal storage in fibroblasts from 11 patients affected by various LSDs, which led to the isolation of TSD in which PGRN demonstrated the best effects in reducing lysosomal storage. Subsequent in vivo studies revealed significant GM2 accumulation and the existence of typical TSD cells containing zebra bodies in both aged and ovalbumin-challenged adult PGRN-deficient mice. In addition, HexA, but not HexB, was aggregated in PGRN-deficient cells. Furthermore, recombinant PGRN significantly reduced GM2 accumulation and lysosomal storage in these animal models. Mechanistic studies indicated that PGRN bound to HexA through granulins G and E domain and increased the enzymatic activity and lysosomal delivery of HexA. More importantly, Pcgin, an engineered PGRN derivative bearing the granulin E domain, also effectively bound to HexA and reduced the GM2 accumulation. Collectively, these studies not only provide new insights into the pathogenesis of TSD but may also have implications for developing PGRN-based therapy for this life-threatening disorder. KEY MESSAGES: GM2 accumulation and the existence of typical TSD cells containing zebra bodies are detected in both aged and ovalbumin-challenged adult PGRN deficient mice. Recombinant PGRN significantly reduces GM2 accumulation and lysosomal storage both in vivo and in vitro, which works through increasing the expression and lysosomal delivery of HexA. Pcgin, an engineered PGRN derivative bearing the granulin E domain, also effectively binds to to HexA and reduces GM2 accumulation.
泰萨二氏症(Tay-Sachs disease,TSD)是一种致命的溶酶体贮积病(lysosomal storage disease,LSD),由 HexA 基因突变引起,可导致β-己糖胺酶 A(HexA)活性缺乏,进而其底物 GM2 神经节苷脂蓄积。最近有报道称颗粒体蛋白(progranulin,PGRN)作为溶酶体酶的伴侣,其缺乏与包括戈谢病(Gaucher disease)和神经元蜡样脂褐质沉积症(neuronal ceroid lipofuscinosis)在内的 LSD 相关,这促使我们筛选重组 PGRN 对各种 LSD 患者成纤维细胞溶酶体贮积的影响,由此分离出 PGRN 对减轻溶酶体贮积效果最好的 TSD。随后的体内研究显示,在老年和卵清蛋白(ovalbumin)挑战的 PGRN 缺陷型成年小鼠中,GM2 蓄积明显,并存在具有斑马体的典型 TSD 细胞。此外,PGRN 缺陷型细胞中仅 HexA 发生聚集,而非 HexB。此外,重组 PGRN 可显著减少这些动物模型中的 GM2 蓄积和溶酶体贮积。机制研究表明,PGRN 通过颗粒体蛋白 G 和 E 结构域与 HexA 结合,并增加 HexA 的酶活性和溶酶体转运。更为重要的是,携带颗粒体蛋白 E 结构域的工程化 PGRN 衍生物 Pcgin 也能有效结合 HexA,并减少 GM2 蓄积。总之,这些研究不仅为 TSD 的发病机制提供了新的见解,也可能为开发基于 PGRN 的这种危及生命的疾病的治疗方法提供了依据。
在老年和卵清蛋白挑战的 PGRN 缺陷型成年小鼠中,均检测到 GM2 蓄积和具有斑马体的典型 TSD 细胞的存在。重组 PGRN 可显著减少体内和体外 GM2 蓄积和溶酶体贮积,其作用机制是通过增加 HexA 的表达和溶酶体转运。携带颗粒体蛋白 E 结构域的工程化 PGRN 衍生物 Pcgin 也能有效结合 HexA 并减少 GM2 蓄积。